Clinical trial
Ketamine as an Adjuvant Therapy for Acute Vaso Occlusive Crisis in Pediatric Patients With Sickle Cell Disease
Abstract
The primary objective of the proposed study is to determine the potential role of Ketamine as an analgesic agent in pediatric sickle cell disease patients with refractory symptoms in acute (VOC).
Topics & conditions
Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.
Keywords
Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.
Related research
ArticleMDMA
Chemsex drugs: More than ghb, mephedrone and methamphetamine?
ArticleKetamine
Midazolam-Ketamine (MK) Versus Propofol-Ketamine (PK) for Pediatric Burn Patients Undergoing Dressing Changes: A Non-Randomized Cross-Over Clinical Trial.
ArticleKetamine